Camptothecin derivatives and uses thereof

By developing a new camptothecin derivative and antibody conjugate, the toxic side effects and unstable treatment effects of existing camptothecin derivatives in the treatment of tumors are solved, and efficient killing and safety of tumor cells is achieved. promote.

CN115850291BActive Publication Date: 2024-11-15CSPC MEGALITH BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211161591.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-09-24
Filing Date
2022-09-22
Publication Date
2024-11-15
Estimated Expiration
2042-09-22

AI Technical Summary

Technical Problem

Existing camptothecin derivatives have toxic side effects and unstable therapeutic effects when treating tumors, especially when individuals vary greatly for different targets, resulting in uneven patient responses.

Method used

Develop a new camptothecin derivative that forms an antibody-drug conjugate by coupling to specific antibodies, using the targeted properties of the antibodies to accurately deliver cytotoxic drugs to tumor cells, enhancing the "bystander" effect, and Improve anti-tumor activity and safety by optimizing compound structure.

Benefits of technology

It achieves efficient killing and inhibiting tumor cells, reduces toxicity to non-tumor cells, improves therapeutic effect and safety, and reduces the dosage of drugs, enhances the anti-tumor effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115850291B_ABST
    Figure CN115850291B_ABST
Patent Text Reader

Abstract

The present invention relates to a compound represented by formula (-Y) and its stereoisomers, geometric isomers, tautomers, pharmaceutically acceptable salts, prodrugs, hydrates, solvates or isotope-labeled analogs, a pharmaceutical composition containing the same, and its use in preparing a method for preventing and / or treating cell proliferative diseases such as cancer, as well as a method for preparing the compound. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to camptothecin derivatives with anti-tumor effect and uses thereof. Background Art

[0002] Antibody-drug conjugate (ADC) consists of three different components (antibody, linker and drug). ADC technology is to couple monoclonal antibody and drug molecules together through linker, and use the antibody's specific targeted transport of drug molecules to target tissues to exert its effects, thereby reducing the drug's systemic toxic side effects, improving the drug's therapeutic window and expanding the therapeutic potential of antibodies.

[0003] Currently, there are more than 200 ADCs in development. ADCs have created a new paradigm for novel cancer chemotherapy. With the specificity of monoclonal antibodies and the cytotoxicity of small molecule drugs, ADCs are expected to become an important part of the future of precision medicine and combination therapy. Therefore, there is a continuous need to provide additional ADCs and means, methods and uses for the treatment and / or diagnosis of diseases.

[0004] Camptothecin (CPT) is a pyrroloquinoline cytotoxic alkaloid and one of the most studied natural anti-tumor drugs besides paclitaxel. It is mainly derived from Camptotheca acuminate Decne, a plant unique to my country. It was first isolated from the stems of Camptotheca acuminate Decne introduced from my country by Wall et al. in 1966. From 1967 to 1970, researchers found that the alkaloid showed strong anti-tumor activity against Hela cells, L1210 cells and rodents in vitro, which attracted great attention. Studies have shown that it has certain therapeutic effects on a variety of malignant tumors such as gastric cancer, rectal cancer and leukemia. However, due to the alkaloid's easy side effects such as nausea, vomiting, diarrhea, and hair loss, and its poor water solubility, the anti-tumor activity is reduced after it is made into a water-soluble sodium salt, etc., which made the clinical research of camptothecin almost stagnant in the mid-to-late 1970s. It was not until 1985 that Hsiang et al. discovered that camptothecin and its derivatives exerted their anti-cancer effects by inhibiting DNA synthesis through topoisomerase (topo Ⅰ) as targets. This caused camptothecin to gain widespread attention again, and many derivatives emerged, becoming a new hotspot in the anti-cancer research field.

[0005] People have been committed to finding highly effective and low-toxic camptothecin derivatives. To date, a series of semi-synthetic and fully synthetic camptothecin derivatives have appeared and entered the clinical application or clinical trial stage, such as hydroxycamptothecin (HCPT), irinotecan (Irinotecan, CPT-11), topotecan (Topoteca, TPT), and 9-aminocamptothecin.

[0006] In recent years, ADC drugs with camptothecin derivatives as warheads have received widespread attention, especially the launch of Enhertu and Sacituzumab govitecan.

[0007]

[0008] Daiichi Sankyo's ADC cytotoxic drug (payload) DXd has a unique mechanism of action. Compared with the common chemotherapy drug irinotecan, its activity is 10 times higher. It has a strong ability to penetrate cell membranes, which enables it to kill nearby cancer cells after killing cancer cells that have swallowed ADC, producing a "bystander effect". Its half-life in the blood is significantly shortened, which helps to reduce the occurrence of toxic side effects. The linker has a high stability, and non-tumor tissues will not be affected by toxic drugs. It can be specifically cleaved by lysosomal proteases that are highly expressed in tumors. Multiple cytotoxic drugs can be coupled to one antibody molecule to increase the drug-antibody ratio (DAR). It provides a new research direction for the development of ADC drugs.

[0009]

[0010] Based on Dxd, people further developed Dxd analogs with excellent anti-tumor effects. Among them, CN111689980A discloses a class of Dxd analogs, whose structures are as follows:

[0011]

[0012] The toxins connected to ADC drugs are highly toxic, and the therapeutic window is also narrow after forming ADC drugs. DS-8021, an ADC drug of Ixitecan developed by Daiichi Sankyo, has been successfully launched. Targeting the HER2 target, DS-8021 uses a single antibody to connect 8 toxins. However, the drugs designed in subsequent clinical trials targeting the Trop2 target have reduced the antibody-drug ratio due to safety issues. However, the reduction in the number of conjugated drugs will also reduce the therapeutic effect of ADC drugs.

[0013] Prodrugs and ADCs require various enzymes and targets, which results in large individual differences, leading to uneven responses of patients to prodrugs and easy toxicity. In order to solve the above problems, developing highly effective and low-toxic camptothecin derivatives to increase the therapeutic effect is the direction of our research. Summary of the invention

[0014] The invention provides a camptothecin derivative and a preparation method and a use method thereof.

[0015] In one aspect, the present invention provides a compound represented by the following formula (-Y) and its stereoisomers, geometric isomers, tautomers, pharmaceutically acceptable salts, prodrugs, hydrates, solvates or isotope-labeled analogs:

[0016]

[0017] in:

[0018] J is selected from: HO-CR 1 R 2 -C(O)-、HO-CR 3 R 4 -CR 5 R 6 -C(O)-、HO-CR 7 R 8 -CR 9 R 10 -A-CR 11 R 12 -C(O), HO-XC(O)-

[0019] Where R 1 is selected from C1-6 alkyl, halogenated C1-6 alkyl, and R 2 Selected from C3-8 cycloalkyl, C1-6 alkylC3-8 cycloalkyl, halogenated C3-8 cycloalkyl, C1-6 alkoxyC3-8 cycloalkyl; or

[0020] R 1 is selected from hydrogen, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy C1-6 alkyl, C3-8 cycloalkyl C1-6 alkyl, halogen, C1-6 alkoxy, halogenated C1-6 alkoxy, C3-8 cycloalkyl, halogenated C3-8 cycloalkyl, and R 2 Selected from hydroxy C1-6 alkyl, mercapto C1-6 alkyl, hydroxy halogenated C1-6 alkyl, mercapto halogenated C1-6 alkyl;

[0021] R 3 , R 4 are the same or different, and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a deuterated C1-6 alkyl group, a C1-6 alkoxy group, a hydroxyl group, an amino group, a cyano group, a nitro group, a hydroxy C1-6 alkyl group, a mercapto C1-6 alkyl group, a C3-8 cycloalkyl group, a halogenated C3-8 cycloalkyl group, a C1-6 alkyl C3-8 cycloalkyl group, a C1-6 alkoxy C3-8 cycloalkyl group, or a 3-8 membered heterocycloalkyl group, R 5 , R 6 is hydrogen;

[0022] A is selected from O or S; R 7 , R 8 , R9 , R 10 , R 11 , R 12 are the same or different, and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a deuterated C1-6 alkyl group, a C1-6 alkoxy group, a hydroxyl group, an amino group, a cyano group, a nitro group, a hydroxy C1-6 alkyl group, a mercapto C1-6 alkyl group, a C3-8 cycloalkyl C1-6 alkyl group, a C3-8 cycloalkyl group, a halogenated C3-8 cycloalkyl group, a C1-6 alkyl C3-8 cycloalkyl group, a C1-6 alkoxy C3-8 cycloalkyl group, or a 3-8 membered heterocycloalkyl group;

[0023] X is a C6-14 aryl group.

[0024] In a preferred embodiment of the present invention, R 1 is selected from C1-6 alkyl, and R 2 is selected from C3-8 cycloalkyl; further preferably R 1 is selected from methyl, ethyl, n-propyl, isopropyl, and R 2 Selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0025] In a preferred embodiment of the present invention, R 1 is selected from hydrogen, and R 2 is selected from hydroxy C1-6 alkyl, mercapto C1-6 alkyl, hydroxy halogenated C1-6 alkyl, mercapto halogenated C1-6 alkyl, C1-6 alkoxy; preferably R 1 is selected from hydrogen, and R 2 is selected from hydroxy C1-6 alkyl, mercapto C1-6 alkyl, and more preferably R 1 is selected from hydrogen, and R 2 Selected from hydroxymethyl, hydroxyethyl, hydroxypropyl such as hydroxy-n-propyl, hydroxyisopropyl, mercaptomethyl, mercaptoethyl, mercaptopropyl such as mercapto-n-propyl, mercaptoisopropyl.

[0026] In a preferred embodiment of the present invention, R 3 and R 4 The same or different, each independently selected from hydrogen, C1-6 alkyl, halogen, halogenated C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyC1-6 alkyl, hydroxyl, C3-8 cycloalkyl.

[0027] In a preferred embodiment of the present invention, A is selected from O or S; R 7 , R 8 , R 9 , R 10 , R 11 , R 12 The same or different, each independently selected from a hydrogen atom, a deuterium atom, a halogen, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a deuterated C1-6 alkyl group, and a C3-8 cycloalkyl group.

[0028] In a preferred embodiment of the present invention, A is selected from O; R 7 , R 8 , R 9 , R 10 , R 11 , R 12 The same or different, each independently selected from a hydrogen atom, a deuterium atom, a halogen, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a deuterated C1-6 alkyl group, and a C3-8 cycloalkyl group.

[0029] In a preferred embodiment of the present invention A is selected from O.

[0030] In a preferred embodiment of the present invention, X is selected from phenyl, naphthyl, phenanthrenyl, anthracenyl; preferably phenyl.

[0031] In a preferred embodiment of the present invention, J can be selected from

[0032]

[0033] In a preferred embodiment of the present invention, the compound represented by formula (-Y), and its stereoisomers, geometric isomers, tautomers, pharmaceutically acceptable salts, prodrugs, hydrates, solvates or isotope-labeled analogs are selected from the following compounds:

[0034]

[0035] Another aspect of the present invention provides a method for preparing a compound represented by formula (-Y), and its stereoisomers, geometric isomers, tautomers, pharmaceutically acceptable salts, prodrugs, hydrates, solvates or isotope-labeled analogs, which comprises the following steps:

[0036]

[0037] Compound J-OH undergoes a condensation reaction with exitecan or a salt thereof as shown in formula (I) to obtain a compound of general formula Y, wherein J is defined as in general formula (-Y), and OH is connected to C(O) in J.

[0038] Another aspect of the present invention provides a compound represented by formula (-Y), and use of its stereoisomers, geometric isomers, tautomers, pharmaceutically acceptable salts, prodrugs, hydrates, solvates or isotope-labeled analogs in the manufacture of antibody-drug conjugates (ADC) drugs.

[0039] Another aspect of the present invention provides a pharmaceutical composition comprising a compound represented by formula (-Y), and its stereoisomers, geometric isomers, tautomers, pharmaceutically acceptable salts, prodrugs, hydrates, solvates or isotope-labeled analogs or antibody-drug conjugates. The pharmaceutical composition further comprises pharmaceutically acceptable excipients and carriers.

[0040] Another aspect of the present invention provides a compound represented by formula (-Y), and its stereoisomers, geometric isomers, tautomers, pharmaceutically acceptable salts, prodrugs, hydrates, solvates or isotope-labeled analogs or antibody-drug conjugates thereof for use in the preparation of drugs for treating proliferative diseases. The proliferative disease includes cancer, and the cancer is preferably selected from breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, stomach cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), colon cancer, rectal cancer, colorectal cancer, leukemia (e.g., acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia) bone cancer, skin cancer, thyroid cancer, pancreatic cancer or lymphoma (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma or relapsed anaplastic large cell lymphoma).

[0041] Another aspect of the present invention provides a method for treating or preventing a proliferative disease, the method comprising administering to a patient in need thereof a therapeutically effective dose of a compound represented by formula (-Y), and its stereoisomers, geometric isomers, tautomers, pharmaceutically acceptable salts, prodrugs, hydrates, solvates or isotope-labeled analogs or antibody-drug conjugates or pharmaceutical compositions comprising the same; the proliferative disease comprises cancer, and the cancer is preferably selected from breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, Cancer, stomach cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), colon cancer, rectal cancer, colorectal cancer, leukemia (e.g., acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia), bone cancer, skin cancer, thyroid cancer, pancreatic cancer, or lymphoma (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma, or relapsed anaplastic large cell lymphoma).

[0042] The camptothecin analogues of the present invention have excellent anti-tumor activity, and have better tumor cell proliferation inhibition effect and better "bystander" effect than Dxd and Dxd derivatives known in the prior art, and have better killing effect on antigen-negative cells next to the tumor.

[0043] By connecting the compound of the present invention to an antibody that can target tumor cells (i.e., an antibody having one or more of the characteristics of being able to recognize tumor cells, being able to bind to tumor cells, being able to internalize into tumor cells, or being cytotoxic to tumor cells) via a linker portion, an antibody-drug conjugate compound is obtained, which can achieve the following effects: if the antibody is cytotoxic to tumor cells, its cytotoxicity can be enhanced. In addition, the anti-tumor compound can be more reliably transferred to tumor cells, so that the anti-tumor effect of the compound is specifically exerted in tumor cells. Therefore, while the anti-tumor effect can be reliably exerted, the amount of the anti-tumor compound administered can be significantly reduced compared to when the compound is administered alone, thereby achieving higher safety.

[0044] definition

[0045] Unless otherwise specified, the term "alkyl" refers to a monovalent saturated aliphatic hydrocarbon group, a straight or branched group containing 1-20 carbon atoms, preferably containing 1-10 carbon atoms (i.e., C1-10 alkyl), further preferably containing 1-8 carbon atoms (C1-8 alkyl), and more preferably containing 1-6 carbon atoms (i.e., C1-6 alkyl). For example, "C1-6 alkyl" means that the group is an alkyl group, and the number of carbon atoms on the carbon chain is between 1-6 (specifically 1, 2, 3, 4, 5 or 6). Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, neopentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, n-heptyl, n-octyl, etc. Unless otherwise specified, the term "cycloalkyl" refers to a monocyclic saturated aliphatic hydrocarbon group having a specific number of carbon atoms, preferably containing 3-12 carbon atoms (i.e., C3-12 cycloalkyl), more preferably containing 3-10 carbon atoms (C3-10 cycloalkyl), further preferably 3-7 carbon atoms (C3-7 cycloalkyl), 4-6 carbon atoms (C4-6 cycloalkyl), 5-6 carbon atoms (C5-6 cycloalkyl). Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, methylcyclopropyl, 2-ethyl-cyclopentyl, dimethylcyclobutyl, etc.

[0046] Unless otherwise specified, the term "alkoxy" refers to -O-alkyl, wherein the alkyl is as defined above, i.e., contains 1-20 carbon atoms, preferably, contains 1-10 carbon atoms, more preferably 1-8 carbon atoms, more preferably 1-6 carbon atoms (specifically 1, 2, 3, 4, 5 or 6). Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, tert-butoxy, pentyloxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, and the like.

[0047] Unless otherwise specified, the term "halogen" or "halo" refers to F, Cl, Br, I. The term "haloalkyl" refers to an alkyl group as defined above in which one, two or more hydrogen atoms or all hydrogen atoms are replaced by halogen. Representative examples of haloalkyl include CCl3, CHCl2, CH2Cl, CF3, CHF2, CH2F, CBr3, CHBr2, CH2Br, CI3, CHI2, CH2I, CH2CF3, CF2CF3, etc.

[0048] Unless otherwise specified, the term "heterocyclyl" or "heterocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic non-aromatic substituent having ring carbon atoms and 1 to 4 ring heteroatoms, containing 3-20 ring atoms, of which 1, 2, 3 or more ring atoms are selected from N, O or S, and the remaining ring atoms are C. Preferably, it contains 3-12 ring atoms (3-12-membered heterocyclyl), further preferably 3-10 ring atoms (3-10-membered heterocyclyl), or 3-8 ring atoms (3-8-membered heterocyclyl), or 3-6 ring atoms (3-6-membered heterocyclyl), or 4-6 ring atoms (4-6-membered heterocyclyl), or 5-6 ring atoms (5-6-membered heterocyclyl). The number of heteroatoms is preferably 1-4, more preferably 1-3 (i.e., 1, 2 or 3). Examples of monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, dihydropyrrolyl, piperidinyl, piperazinyl, pyranyl, etc. Polycyclic heterocyclic groups include spiro, fused and bridged heterocyclic groups. "Heterocyclic group" can be a monocyclic ("monocyclic heterocyclic group") or a fused ("fused heterocyclic group" or "heterofused group"), bridged ("heterobridged group" or "bridged heterocyclic group") or spiro-fused ("heterospirocyclic group" or "spirocyclic heterocyclic group") ring system, such as a bicyclic system ("bicyclic heterocyclic group"), and can be saturated or partially unsaturated. Heterocyclic bicyclic systems can include one or more heteroatoms in one or both rings. "Heterocyclyl" also includes ring systems in which the heterocyclyl ring as defined above is fused with one or more carbocyclyl groups, wherein the point of attachment is on the carbocyclyl or heterocyclyl ring, or "heterocyclyl" also includes ring systems in which the heterocyclyl ring as defined above is fused with one or more aryl or heteroaryl groups, or cycloalkyl rings as defined above are fused with one or more heteroaryl groups, wherein the point of attachment is on the heterocyclyl or cycloalkyl ring, and in such cases, the number of members of the heterocyclyl ring system is the number of atoms in the ring system after fusion. In certain embodiments, each instance of heterocyclyl is independently optionally substituted, e.g., unsubstituted (an "unsubstituted heterocyclyl") or substituted with one or more substituents (a "substituted heterocyclyl"). Exemplary 3-membered heterocyclyl groups containing 1 heteroatom include, but are not limited to, aziridine, oxiranyl, and thiorenyl. Exemplary 4-membered heterocyclyl groups containing 1 heteroatom include, but are not limited to, azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclyl groups containing 1 heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrophenylthio, dihydrophenylthio, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groups containing 2 heteroatoms include, but are not limited to, dioxolanyl, oxathiolanyl, dithiolanyl, and oxazolidin-2-one.Exemplary 5-membered heterocyclic radicals containing 3 heteroatoms include, but are not limited to triazolinyl, oxadiazolinyl and thiadiazolinyl. Exemplary 6-membered heterocyclic radicals containing 1 heteroatom include, but are not limited to piperidinyl, tetrahydropyranyl, dihydropyridinyl and thianyl. Exemplary 6-membered heterocyclic radicals containing 2 heteroatoms include, but are not limited to piperazinyl, morpholinyl, dithiacyclohexane and dioxacyclohexane. Exemplary 6-membered heterocyclic radicals containing 3 heteroatoms include, but are not limited to triazacyclohexane, oxadiazine alkyl, thiadiazine alkyl, oxathiazine alkyl and dioxaazacyclohexane alkyl (dioxazinanyl). Exemplary 7-membered heterocyclic radicals containing 1 heteroatom include, but are not limited to azepanyl, oxacycloheptanyl and thianyl. Exemplary 8-membered heterocyclyl groups containing 1 heteroatom include, but are not limited to, azocanyl, oxocanyl, and thiocanyl. Exemplary 5-membered heterocyclyl groups fused to a C6 aryl ring (also referred to herein as a 5,6-bicyclic heterocycle) include, but are not limited to, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinone, and the like. Exemplary 6-membered heterocyclyl groups fused to an aryl ring (also referred to herein as a 6,6-bicyclic heterocycle) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.

[0049] Unless otherwise specified, "heterocycloalkyl" refers to a monocyclic, saturated "heterocyclyl" or "heterocycle" as defined above, with the same ring atoms as defined above, i.e., containing 3-20 ring atoms ("3-20 membered heterocycloalkyl"), with 1-4 (1, 2, 3 or 4) heteroatoms, preferably 1-3 (1, 2 or 3), wherein each heteroatom is independently selected from N, O or S. Preferably, it contains 3-12 ring atoms ("3-12 membered heterocycloalkyl"), further preferably contains 3-10 ring atoms ("3-10 membered heterocycloalkyl"), further preferably contains 3-8 ring atoms ("3-8 membered heterocycloalkyl"), further preferably contains 4-7 ring atoms ("4-7 membered heterocycloalkyl"), further preferably contains 5-10 ring atoms ("5-10 membered heterocycloalkyl"), further preferably contains 5-6 ring atoms ("5-6 membered heterocycloalkyl"). In certain embodiments, each example of heterocycloalkyl is independently optionally substituted, for example, unsubstituted (an "unsubstituted heterocycloalkyl") or substituted with one or more substituents (a "substituted heterocycloalkyl"). Some exemplary "heterocycloalkyl" are given in the "heterocyclyl" or "heterocycle" section above, and also include, but are not limited to, aziridine, oxirane, thiirane, azetidinyl, oxetanyl, thietanyl, tetrahydrofuranyl, oxanyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, oxathiolanyl, oxazolidinyl, dioxanyl, dithiolanyl, thiazolidinyl, pyrrolidinyl, pyrazolidinyl, imidazolinyl, and the like.

[0050] Unless otherwise specified, the term "aryl" or "aromatic ring group" refers to a monocyclic, bicyclic and tricyclic aromatic carbocyclic ring system containing 6-16 carbon atoms, or 6-14 carbon atoms, or 6-12 carbon atoms, or 6-10 carbon atoms, preferably 6-10 carbon atoms, and the term "aryl" can be used interchangeably with the term "aromatic ring". Examples of aryl groups may include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthrenyl or pyrenyl, etc.

[0051] Unless otherwise specified, the term "heteroaryl" or "heteroaromatic ring group" means an aromatic monocyclic or polycyclic ring system containing 5-14 membered structures, or preferably 5-10 membered structures, or preferably 5-8 membered structures, more preferably 5-6 membered structures, wherein 1, 2, 3 or more ring atoms are heteroatoms and the remaining atoms are carbon, the heteroatoms are independently selected from O, N or S, and the number of heteroatoms is preferably 1, 2 or 3. Examples of heteroaryl groups include, but are not limited to, furanyl, thienyl, oxazolyl, thiazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiodiazolyl, triazinyl, phthalazinyl, quinolyl, isoquinolyl, pteridinyl, purinyl, indolyl, isoindolyl, indazolyl, benzofuranyl, benzothiophenyl, benzopyridinyl, benzopyrimidinyl, benzo pyrazinyl, benzimidazolyl, benzophthalazinyl, pyrrolo[2,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridinyl, and the like.

[0052] Unless otherwise specified, the term "pharmaceutically acceptable salt" or "pharmaceutically acceptable salt" refers to salts that are suitable for contact with mammalian, especially human tissues without excessive toxicity, irritation, allergic reaction, etc. and commensurate with a reasonable benefit / risk ratio within the scope of reasonable medical judgment, such as amines, carboxylic acids and other types of medically acceptable salts of compounds are well known in the art. The salts can be prepared in situ during the final isolation and purification of the compounds of the present invention, or separately by reacting the free base or free acid with a suitable reagent.

[0053] Unless otherwise specified, the term "isotopic derivative" means that the compounds of the present invention may exist in an isotopically traced or enriched form, containing one or more atoms whose atomic mass or mass number is different from the atomic mass or mass number of the largest atom found in nature. Isotopes may be radioactive or non-radioactive isotopes. Isotopes commonly used as isotopic labels are: hydrogen isotopes, 2 H and 3 H; Carbon isotope: 13 C and 14 C; Chlorine isotope: 35 Cl and 37 Cl; Fluorine isotope: 18 F; Iodine isotope: 123 I and 125 I; Nitrogen isotopes: 13 N and 15 N; oxygen isotope: 15O, 17 O and 18 O and sulfur isotopes 35 S. These isotope-labeled compounds can be used to study the distribution of drug molecules in tissues. 2 H and 13 C, because they are easy to label and convenient to detect, they are more widely used. Certain heavy isotopes, such as deutrium (2H), can enhance metabolic stability, prolong half-life, and thus achieve the purpose of reducing dosage and provide therapeutic advantages. Isotope-labeled compounds are generally synthesized from labeled starting materials using known synthetic techniques in the same way as non-isotope-labeled compounds.

[0054] Unless otherwise specified, the terms "solvate" and "solvate" mean a physical association of a compound of the invention with one or more solvent molecules, whether organic or inorganic. The physical association includes hydrogen bonding. In certain cases, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid, the solvate will be able to be separated. The solvent molecules in the solvate may exist in a regular arrangement and / or a disordered arrangement. The solvate may contain stoichiometric or non-stoichiometric amounts of solvent molecules. "Solvate" encompasses solution phases and separable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Solvation methods are well known in the art.

[0055] Unless otherwise specified, the term "stereoisomer" refers to compounds with the same chemical constitution but different arrangements of atoms or groups in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric isomers (cis / trans) isomers, atropisomers, etc. Any resulting mixture of stereoisomers can be separated into pure or substantially pure geometric isomers, enantiomers, diastereomers, for example, by chromatography and / or fractional crystallization based on the differences in the physical and chemical properties of the components.

[0056] Unless otherwise specified, the term "tautomer" refers to structural isomers with different energies that can be interconverted through a low energy barrier. If tautomerism is possible (such as in solution), a chemical equilibrium of tautomers can be achieved. For example, proton tautomers (also known as prototropic tautomers) include interconversions by proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions by reorganization of some of the bonding electrons.

[0057] Unless otherwise indicated, the structural formulas described in the present invention include all isomeric forms (such as enantiomers, diastereomers, and geometric isomers (or conformational isomers): for example, R, S configurations containing asymmetric centers, (Z), (E) isomers of double bonds, and (Z), (E) conformational isomers. Therefore, single stereochemical isomers of the compounds of the present invention or mixtures of their enantiomers, diastereomers, or geometric isomers (or conformational isomers) are all within the scope of the present invention.

[0058] Unless otherwise specified, the term "prodrug" refers to a drug that is converted into the parent drug in vivo. Prodrugs are generally useful and can improve some certain, undesirable physical or biological properties. Physical properties are generally related to solubility (too high or insufficient lipid or water solubility) or stability, while problematic biological properties include too rapid metabolism or poor bioavailability, which may themselves be related to physicochemical properties. For example, they can be bioavailable by oral administration, while the parent cannot. The solubility of the prodrug in the pharmaceutical composition is also improved compared to the parent drug. An example of a prodrug, but not limited to this, can be any compound of the present invention, which is administered as an ester ("prodrug") to facilitate transmission across the cell membrane, where water solubility is detrimental to mobility, but once inside the cell, water solubility is beneficial, which is then metabolically hydrolyzed to the carboxylic acid, the active entity. Another example of a prodrug can be a short peptide (polyamino acid) bound to an acid group, where the peptide is metabolized to reveal the active portion. DETAILED DESCRIPTION

[0059] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are usually performed under conventional conditions or according to the conditions recommended by the manufacturer. Unless otherwise defined, all professional and scientific terms used in the text have the same meanings as those familiar to professionals in the field. In addition, any method and material similar or equivalent to the described content can be applied to the method of the present invention. The preferred implementation methods and materials shown in the text are for demonstration purposes only.

[0060] The structure of the compound of the present invention is determined by nuclear magnetic resonance (NMR) or / and liquid chromatography-mass spectrometry (LC-MS) or / and liquid chromatography (HPLC). The instrument used for NMR determination is a Bruker Avance III 400MHz nuclear magnetic resonance instrument; the instrument used for LC-MS is a SHIMADZU LC-20AD-PDA-LCMS-2020; and the instrument used for HPLC is a SHIMADZU LC-20AD-PDA high performance liquid chromatograph.

[0061] The starting materials in the examples of the present invention are known and can be purchased on the market, or can be synthesized by or according to methods known in the art.

[0062] Example 1

[0063] N-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)-2-hydroxybenzamide (Compound 1)

[0064]

[0065] In a 25 mL single-mouth flask, raw material R2 (12 mg, 0.09 mmol, 1.0 eq), exitecan mesylate (50 mg, 0.09 mmol, 1.0 eq), 1H-benzotriazol-1-yloxytripyrrolidino hexafluorophosphate (73 mg, 0.14 mmol, 1.5 eq), N,N-diisopropylethylamine (19 mg, 0.14 mmol, 1.5 eq), N,N-dimethylformamide (1 The mixture was stirred at room temperature overnight and sent to preparative HPLC to obtain the target product N-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)-2-hydroxybenzamide (Compound 1) (26.45 mg).

[0066] LC-MS [M+H]+: m / z 556.2.

[0067] 1 H NMR (400MHz, DMSO-d6): δ12.20(s,1H),9.22(d,J=8.3Hz,1H),7.89(d,J=6.6Hz,1H),7.8 2(d,J=11.0Hz,1H),7.42(t,J=7.8Hz,1H),7.31(s,1H),6.94(d,J=7.6Hz,1H),6.87(t,J= 7.3 Hz, 1H), 6.72-6.00 (m, 1H), 5.83 (s, 1H), 5.37 (s, 2H), 5.23 (q, J = 18.9 Hz, 2H), 3.23-3.19 (m, 2H), 2.42 (s, 3H), 2.32 (d, J = 6.5 Hz, 2H), 1.93-1.72 (m, 2H), 0.86 (t, J = 7.3 Hz, 3H). Example 2

[0068] 2-Cyclopropyl-N-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[[1,2-b]quinolin-1-yl)-2-hydroxypropanamide (Compound 2)

[0069]

[0070] Step 1: Preparation of compound R3: 3a (50 mg, 0.44 mmol) and 3 mL of tetrahydrofuran were added to a 50 mL single-mouth bottle and stirred in an ice bath. When the temperature reached 0°C, methylmagnesium bromide (1 M in THF; 1.1 mL, 1.10 mmol) was added dropwise. The solution was stirred at room temperature overnight. The reaction solution was then cooled to 0°C and quenched with 1N HC1 (10 mL). The reaction solution was stirred at room temperature for 2 hours, and then extracted twice with ethyl acetate (2*15 mL). The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then concentrated to obtain product R3 (52 mg). 1H NMR (400 MHz, CDC13) 1.50 (s, 3H), 1.19-1.33 (m, 1H), 0.35-0.55 (m, 4H).

[0071] Step 2: Preparation of compound 2: In a 25 mL single-mouthed flask, raw material R3 (36 mg, 0.28 mmol, 1.5 eq), exitecan mesylate (100 mg, 0.19 mmol, 1.0 eq), 1H-benzotriazol-1-yloxytripyrrolidino hexafluorophosphate (196 mg, 0.38 mmol, 2.0 eq), N,N-diisopropylethylamine (72 mg, 0.56 mmol, 3.0 eq), N,N-dimethyl Formamide (1 mL) was stirred at room temperature overnight and sent to preparative HPLC to give the target product 2-cyclopropyl-N-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[[1,2-b]quinolin-1-yl)-2-hydroxypropanamide (Compound 2) (25.2 mg).

[0072] LC-MS [M+H]+: m / z 548.2.

[0073] 1H NMR (400MHz, MeOD-d4): δ8.53(d,J=9.2Hz,0.5H),8.44(d,J=9.2Hz,0.5H),7.60(s,0.5H),7.59(s ,0.5H),7.56(s,J=4.4Hz,0.5H),7.54(s,J=4.4Hz,0.5H),5.53-5.66(m,2H),5.30-5.37(m,2H),4. 90-4.79(m,1H),3.09-3.19(m,1H),2.39(s,3H),2.31-2.36(m,1H),2.10-2.24(m,1H),1.91-1.98( m,2H),1.61(s,1.5H),1.46(s,1.5H),1.24-1.41(m,2H),1.00(t,J=7.2Hz,3H),0.33-0.64(m,4H).

[0074] Example 3

[0075] N-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[[1,2-b]quinolin-1-yl)-3-hydroxypropanamide (Compound 3)

[0076]

[0077]

[0078] Step 1: Preparation of compound R4: Add sodium hydroxide (120 mg, 3.0 mmol) and water (3 mL) into a 50 mL single-necked bottle and stir to dissolve. Then add β-propiolactone (324 mg, 4.5 mmol) dropwise at room temperature. The reaction solution is stirred at room temperature for 30 minutes, extracted twice with ethyl acetate (10 mL*2), and the aqueous layer is concentrated and dried to obtain a crude product of R4 (195 mg).

[0079] Step 2: Preparation of compound 3: In a 25 mL single-mouth bottle, crude raw material R4 (25 mg, 0.22 mmol, 1.5 eq), exitecan mesylate (80 mg, 0.15 mmol, 1.0 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (74 mg, 0.19 mmol, 1.3 eq), N,N-diisopropylethylamine (58 mg, 0.45 mmol, 3.0 eq), N,N-dimethylformamide (50 mg, 0.45 mmol, 3.0 eq), The amide (1.5 mL) was stirred at room temperature overnight and sent to preparative HPLC to give the target product N-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[[1,2-b]quinolin-1-yl)-3-hydroxypropanamide (Compound 3) (25.39 mg). LC-MS[M+H]+: m / z 508.1.

[0080] 1 H NMR (400MHz, DMSO-d6): δ8.43(d,J=8.4Hz,1H),7.80(d,J=10.8Hz,1H),7.31(s,1H),6.51(brs,1H),5.54-5.59(m,1H),5.42(s,2H),5.22(d,J=3 .6Hz,2H),3.63-3.69(m,2H),3.16-3.18(m,2H),2.41(s,3H),2.32(t,J= 6.4Hz,2H),2.10-2.18(m,2H),1.81-1.92(m,2H),0.87(t,J=7.2Hz,3H).

[0081] Example 4

[0082] (N-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)-2-(2-hydroxyethoxy)acetamide (Compound 4)

[0083]

[0084] In a 25 mL single-mouth bottle, raw material R5 (16 mg, 0.11 mmol, 1.2 eq), exitecan mesylate (50 mg, 0.094 mmol, 1.0 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (43 mg, 0.11 mmol, 1.2 eq), N,N-diisopropylethylamine (36 mg, 0.28 mmol, 3.0 eq), N,N-dimethylformamide The mixture was stirred at room temperature overnight and sent to preparative HPLC to obtain the target product (N-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)-2-(2-hydroxyethoxy)acetamide (Compound 4) (19.98 mg).

[0085] LC-MS [M+H]+: m / z 538.2.

[0086] 1 H NMR (400MHz, MeOD-d4): δ8.72(d,J=8.8Hz,1H),7.64(d,J=10.8Hz,1H),7.62(s ,1H),5.68-5.75(m,1H),5.57(d,J=16.4Hz,1H),5.33-5.39(m,2H),5.11(d,J= 19.2Hz,1H),4.14-4.28(q,2H),3.66(s,4H),3.31-3.37(m,1H),3.15-3.29(m, 1H), 2.42 (s, 3H), 2.19-2.40 (m, 2H), 1.92-1.99 (m, 2H), 1.00 (t, J = 7.6Hz, 3H).

[0087] Example 5

[0088] (R)-N-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[[1,2-b]quinolin-1-yl)-2,3-dihydroxypropionamide (Compound 5)

[0089]

[0090] In a 25 mL single-mouth bottle, raw material R6 (12 mg, 0.094 mmol, 1.0 eq), exitecan mesylate (50 mg, 0.094 mmol, 1.0 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (43 mg, 0.11 mmol, 1.2 eq), N,N-diisopropylethylamine (36 mg, 0.28 mmol, 3.0 eq), N,N-dimethylformamide The mixture was stirred at room temperature overnight and sent to preparative HPLC to obtain the target product (R)-N-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[[1,2-b]quinolin-1-yl)-2,3-dihydroxypropionamide (Compound 5) (22.92 mg).

[0091] LC-MS [M+H]+: m / z 524.2.

[0092] 1 H NMR (400MHz, DMSO-d6): δ8.36(d,J=9.2Hz,1H),7.79(d,J=11.2Hz,1H),7. 30(s,1H),6.51(s,1H),5.54-5.59(m,2H),5.42(s,2H),5.12-5.27(q,2H) ,4.65(brs,1H),3.99-4.01(m,1H),3.63-3.72(m,2H),3.14-3.19(m,2H), 2.39(s,3H),2.12-2.22(m,2H),1.82-1.90(m,2H),0.87(t,J=7.2Hz,3H).

[0093] Example 6 (reference example)

[0094] N-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[[1,2-b]quinolin-1-yl)-2-hydroxyacetamide (Compound Dxd)

[0095]

[0096] The title compound Dxd was purchased from Shanghai Haoyuan Pharmaceutical Co., Ltd.

[0097] Example 7 (reference example)

[0098] (R)-N-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[[1,2-b]quinolin-1-yl)-2-hydroxypropanamide (Compound A)

[0099]

[0100] In a 25 mL single-mouthed flask, the raw material R1 (13 mg, 0.14 mmol, 1.5 eq), exitecan mesylate (50 mg, 0.09 mmol, 1.0 eq), 1H-benzotriazol-1-yloxytripyrrolidino hexafluorophosphate (73 mg, 0.14 mmol, 1.5 eq), N,N-diisopropylethylamine (19 mg, 0.14 mmol, 1.5 eq), N,N-dimethylformamide (1 mL ) was stirred at room temperature overnight and sent to preparative HPLC to give the target product (R)-N-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[[1,2-b]quinolin-1-yl)-2-hydroxypropanamide (Compound A) (22.93 mg).

[0101] LC-MS [M+H]+: m / z 508.3.

[0102] 1 H NMR (400MHz, DMSO-d6): δ8.43(d,J=9.1Hz,1H),7.77(d,J=11.0Hz,1H),7.30(s,1H),6.5 1(s,1H),5.57(dd,J=13.9,8.7Hz,2H),5.42(s,2H),5.24(d,J=19.0Hz,1H),5.07(d,J=1 8.9Hz,1H),4.13(d,J=6.7Hz,1H),3.21(s,1H),3.18-3.02(m,1H),2.38(s,3H),2.18(t, J=8.6Hz,2H),1.86(tt,J=14.1,7.2Hz,2H),1.40(d,J=6.8Hz,3H),0.87(t,J=7.3Hz,3H).

[0103] Biological Examples

[0104] 1. Test method for in vitro tumor cell proliferation inhibition activity: In vitro proliferation inhibition activity of MDA-MB-468 (ATCC / HTB-132), T47D, SK-BR-3 (ATCC / HTB-30), Bxpc-3, A375, CHOK1 tumor cells. Tumor cells were treated with different concentrations of compounds in vitro. After 3 days of culture, Resazurin was added and the fluorescence values ​​of ex550nm / em610nm were read. The IC was obtained by four-parameter fitting processing of the data. 50 The biological activity of the compound can be calculated.

[0105] 2. Experimental materials and equipment:

[0106] Material

[0107] Product Name Manufacturer / Article No. SK-BR-3 cell line ATCC / HTB-30 MDA-MB-468 ATCC / HTB-132 T47D Kebai Bio / CBP60397 Bxpc-3 ATCC / CRL-1687 A375 CellPac / iCell-h007 CHOK1 ATCC / CCL-61 DMEM, high glucose Hyclone / SH30022.01 0.25%Trypsin-EDTA Gibco / 25200-072 Fetal bovine serum (FBS) Gibco / 16000-044 100× double antibody Gibco / 15240-062 Black wall, clear bottom tissue culture plates Corning / 3603 Resazurin Sodium Sigma Aldrich / 199303-25G

[0108] equipment

[0109]

[0110]

[0111] 3. Experimental operation method:

[0112] 3.1 Culture medium: DMEM, 10% FBS, 1× double antibody

[0113] 3.2 Cell culture: Take out a frozen SK-BR-3 / MDA-MB-468 cell from liquid nitrogen and resuscitate to 75cm 2 The cells were grown in culture flasks until they were >75% confluent and had been passaged at least 3 times.

[0114] 3.2.1 If cell subculture is not performed, replace the culture medium every 3 to 4 days.

[0115] 3.2.2 If expansion of cells is required, subculture the cells into larger culture flasks and allow the cells to reach a confluence of >75% before use in the assay.

[0116] 3.3 Collect cells: Collect SK-BR-3 / MDA-MB-468 cells when the culture flask is nearly full.

[0117] 3.3.1 Discard the culture medium and wash with PBS to remove dead cells and residual culture medium.

[0118] 3.3.2 Add 2-3 mL of 0.25% Trypsin-EDTA, gently shake the culture flask and incubate at 37°C for 2-3 minutes to digest the cells.

[0119] 3.3.3 Immediately add 5 mL of culture medium to the culture flask and gently pipette up and down to disperse the cells.

[0120] 3.3.4 Transfer the cell suspension into a sterile centrifuge tube and centrifuge at 200×g for 3 minutes.

[0121] 3.3.5 Discard the culture medium in the tube and add 5-10 mL of fresh culture medium to resuspend the cells.

[0122] 3.4 Determination of cell density: Count the cells using a cell counting plate under a microscope.

[0123] 3.5 Inoculation of assay plates

[0124] 3.5.1 Dilute the cells to 1×10 5 cells / mL, and 100 μL / well was seeded into the assay plate (except rows A and H).

[0125] 3.5.2 Add 120 μL of culture medium to each well in rows A and H as blank controls.

[0126] 3.5.3 Incubate at 37℃, 5% CO2 for 4-6 hours to allow cells to adhere.

[0127] 3.6 Prepare diluted compound samples

[0128] The compound was diluted to a starting concentration of 18 μg / ml and then diluted 3 times to obtain 11 gradient solutions in total, with the 12th column being a blank control.

[0129] 3.7 Dosing treatment

[0130] 3.7.1 Take 20 μL of the drug dilutions in columns 1 to 11 of the dilution plate and add them to columns 1 to 11 of the analysis plate.

[0131] 3.7.2 Add 20 μL of fresh culture medium to column 12 and rows A and H.

[0132] 3.7.4 Gently shake the plate on a plate shaker for 10-15 seconds and then incubate the plate at 37°C for 3 days.

[0133] 3.8 Analysis

[0134] 3.8.1 After the incubation, add 20 μL of 0.03% resazurin (diluted with 1× PBS) to each well and shake gently for 10 to 15 seconds.

[0135] 3.8.2 After incubation at 37℃ for 3-4 hours, read the microplate reader and set the parameters as follows:

[0136] Excitation light: 550nm

[0137] Emitted light: 610nm

[0138] Credit time: 50

[0139] Shake: 15 seconds, vortex

[0140] Reading: Top reading

[0141] Read times / well: 1

[0142] Gain: Set optimally (should be between 35 and 42)

[0143] If you are reading multiple boards, make sure the gain setting used is the same for all boards.

[0144] 3.8.3 Use EXCEL data to draw a graph to fit the IC values ​​of reference standards and samples 50 .

[0145] 3.8.3.1 Use model 201 to plot data points.

[0146] 3.8.3.2 For the Fit parameter, use the following command:

[0147] aA: Provisioning

[0148] bB: Provisioning

[0149] cC: Provisioning

[0150] dD: Provisioning

[0151] e. No constraints for all

[0152] 3.8.3.3 Output parameter C is IC 50 , unit is ng / mL.

[0153] The experimental operation methods of other tumor cells are the same as those of SK-BR-3 / MDA-MB-468 cells mentioned above.

[0154] 4. Experimental data:

[0155] Table 1: IC values ​​of the compounds of the present invention, Dxd and compound A on MDA-MB-468 cells 50 value.

[0156]

[0157]

[0158] Note: (1) Due to the limitation of the test method, one or two compounds of the present invention were used for comparison test with Dxd each time, but the IC value of Dxd in each batch of test was 50 values ​​are not exactly the same, so the IC values ​​of Dxd listed in Table 1 are 50The values ​​are the IC values ​​obtained for these comparison tests. 50 (2) In the table, <1 means that the test curve of the compound is incomplete, but the activity is better than Dxd. (3) Compound A is the compound disclosed in CN112125915A.

[0159] Table 2: IC of the compounds of the present invention, Dxd and compound A on SK-BR-3 cells 50 value.

[0160] <![CDATA[IC of Dxd 50 Value (ng / mL)]]> Between 11.971 and 65.290 Compound No. <![CDATA[IC of the compound of the present invention 50 value and the IC of Dxd 50 ratio]]> 1 0.5533 2 0.3202 A 0.7199

[0161] Note: (1) Due to the limitation of the test method, one or two compounds of the present invention were used for comparison test with Dxd each time, but the IC value of Dxd in each batch of test was 50 values ​​are not exactly the same, so the IC values ​​of Dxd listed in Table 2 are 50 The values ​​are the IC values ​​obtained for these comparison tests. 50 (2) Compound A is the compound disclosed in CN112125915A.

[0162] From the data in Table 1 and Table 2, it can be seen that the compounds of the present invention have lower IC than Dxd and compound A. 50 value, showing better anti-cell proliferation effect.

Claims

1. The following compounds and their pharmaceutically acceptable salts or isotope-labeled substances:

2. A pharmaceutical composition comprising the compound according to claim 1 and its pharmaceutically acceptable salt or isotope-labeled substance, and a pharmaceutically acceptable carrier.

3. Use of the compound according to claim 1 and its pharmaceutically acceptable salt or isotope-labeled substance or the pharmaceutical composition according to claim 2 in the preparation of a medicament for preventing and / or treating a proliferative disease.

4. The use according to claim 3, characterized in that: The proliferative disease is cancer.

5. The method of claim 4, wherein the cancer is selected from breast cancer, ovarian cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, stomach cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer, colon cancer, rectal cancer, leukemia, bone cancer, skin cancer, thyroid cancer, pancreatic cancer or lymphoma.

6. The use according to claim 4, wherein the cancer is selected from cervical cancer or endometrial cancer.

7. The method of claim 5, wherein the lung cancer is selected from small cell lung cancer or non-small cell lung cancer, the leukemia is selected from acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, and the lymphoma is selected from Hodgkin's lymphoma, non-Hodgkin's lymphoma or relapsed anaplastic large cell lymphoma.

8. A method for preparing the compound as claimed in claim 1 and its pharmaceutically acceptable salt or isotope-labeled product, comprising the following steps: in, J is selected from: